Conduct↦Safety↦Medicinal Product Safety Reporting↦(Serious) Adverse Drug Reaction
What is it? Why is it important?
An Adverse Drug Reaction (ADR) is an AE that has a causal relationship with the Investigational Medicinal Product (IMP) under investigation.
An ADR is any noxious and unintended response to a drug and which occurs:
- At any dose during Phase I-III studies (e.g. studies testing newly developed IMPs, or licensed MPs not used as approved)
- At doses normally used and approved during studies with a licensed MP (e.g. used as approved)
An ADR is considered serious (SADR) if the event:
- Results in death
- Is life-threatening
- Requires in-patient hospitalization or prolongation of existing hospitalisation
- Results in persistent or significant disability/incapacity, or
- Is a congenital anomaly / birth defect
The WHO defines a MP or drug as:
Any substance (other than food) that is used to prevent, diagnose, treat, or relieve symptoms of a disease or abnormal condition.
What do I need to do?
As a Site-INV:
- In the event of a serious ADR (SADR) follow same reporting procedures as described for SAE
As a SP-INV:
- Follow SAE reporting procedures
- In the event of an unexpected SADR (e.g. based on the RSI: IB for non-licensed IMPs, product information for licensed MPs), follow reporting procedures described for SUSAR
- For category A studies, report all SADRs to Swissmedic within 15 days (e.g. through the Pharmacovigilance (PV) drug safety department, or the PV unit at your hospital)
- For first pilot phase TrP / GT / GMO studies, report all SADR to Swissmedic within 15 days
Documentation and reporting starts and is mandatory once the participant has signed the ICF until:
- Study termination (e.g. last study participant at last study visit), or
- The end of some predefined safety follow-up period (e.g. as defined in the study protocol)
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
External Links
Swissethics – see in particular
- Templates and checklists / Notification
- SAE medicinal products
Swissmedic – see in particular information sheet
- BM101_10_002e_MB FAQ on clinical trials with medicinal products
References
ICH GCP E2A – see in particular guidelines
- Chapter II Definition
ICH GCP E6(R2) – see in particular guidelines
- 1.1 ADR definition
- 1.50 Serious ADR definition
- 1.60 Unexpected ADR
- 5.17 ADR reporting
- 7.3.7 Summary of data and guidance for the investigator
**Swiss Law**
ClinO – see in particular article
- Art. 40 Documentation and reporting of SAE